Microfluidics-Enabled Antibody Discovery: Expediting Cancer and Immunology Research
Summary of Recent Advances in Microfluidic-Assisted Antibody Screening
Discover how Cyto-Mine® technology by Sphere Bio enhances antibody discovery with speed and precision. This 2021 study, published in mAbs, highlights how our microfluidics technology supports a “function first” screening approach of antibody-secreting cells, providing rapid identification of therapeutic candidates in just weeks.
Research highlights
- Study Title: Versatile and Rapid Microfluidics-Assisted Antibody Discovery
- Authors: Ramona Gaa, Emmanuel Menang-Ndi, Shruti Pratapa, Christine Nguyen, Satyendra Kumar, Achim Doerner
- Published In: mAbs Journal, 2021
- DOI: 10.1080/19420862.2021.1978130
Key findings
Additional Highlights
The Next Generation: Cyto-Mine® Chroma
Automate. Accelerate. Analyze millions of cells in a single day.
Think Cyto-Mine®, but supercharged, enabling multiplexing and greater assay flexibility to fit your needs. It means that you can examine vastly greater numbers of cells — and isolate the most valuable ones— with unparalleled precision.